CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals

AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for HIV/HCV coinfected people, according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

Read more:

AASLD 2016: HIV/HCV Coinfected People See Good Cure Rates in Real-World Practice in Madrid

More than 90% of HIV-positive people treated with direct-acting antivirals for hepatitis C -- including many with liver cirrhosis -- achieved sustained virological response and few discontinued treatment due to side effects, showing that real-world clinical practice can produce results as good as those seen in formal clinical trials, according to results from a Spanish study presented at the AASLD Liver Meeting this month in Boston.

Read more:

CROI 2017: New HCV Infections Among HIV+ Gay Men Drop By Half After DAA Roll-Out in Netherlands

A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals (DAAs) for the hepatitis C treatment, researchers have already seen a dramatic decline in acute HCV infections among one at-risk population, HIV-positive men who have sex with men, according to findings reported at the Conference on Retroviruses and Opportunistic Infections this week in Seattle. 

Read more:

Coverage of the 2016 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.

Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.

Full coverage listing by topic

The Liver Meeting website

11/20/16

CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?

HIV/HCV coinfected people who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

Read more:

Coverage of IDWeek 2016

HIVandHepatitis.com coverage of IDWeek 2016, held October 26-30 in New Orleans.

Conference highlights include experimental HIV therapies, PrEP and other biomedical HIV prevention, antibiotic resistance, and emerging infectious diseases such as Ebola virus and Zika virus.

Full listing of coverage by topic

IDWeek website

11/4/16

AASLD 2016: Sofosbuvir/ Ledipasvir Effective for HIV/HCV Coinfected People in Real-World Cohorts

The sofosbuvir/ledipasvir (Harvoni) coformulation used in real-world clinical practice produced good sustained virological response rates similar to those seen in clinical trials for HIV-positive people coinfected with hepatitis C, according to a pooled analysis presented at the 2016 AASLD Liver Meeting this month in Boston.

Read more:

Improved HIV Treatment Has Not Reduced End-Stage Liver Disease in HIV/HCV Coinfected People

Incidence of end-stage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the U.S. report in the November 1 edition of Clinical Infectious Diseases. 

Read more: